Risk Factors for Linezolid Resistance in Staphylococcus Aureus - Full Text View

Purpose

This is a retrospective chart review study. The proposed study aims to document the risk factors for quinolone resistance in bloodstream isolates of Klebsiella species. Additionally, the adequacy of empiric antibiotic therapy for Klebsiella bloodstream infections will be assessed.

Condition

Linezolid Resistance
Staphylococcus Aureus

ChemIDplus related topics:

Linezolid

U.S. FDA Resources

Study Type:	Observational
Study Design:	Cohort, Retrospective

Official Title:	Risk Factors for Linezolid Resistance in Staphylococcus Aureus

Further study details as provided by University of Pittsburgh:

Biospecimen Retention: None Retained

Biospecimen Description:

Estimated Enrollment:	360
Study Start Date:	August 2007
Estimated Study Completion Date:	August 2007

Detailed Description:

This is a retrospective chart review study. The proposed study aims to document the risk factors for quinolone resistance in bloodstream isolates of Klebsiella species. Additionally, the adequacy of empiric antibiotic therapy for Klebsiella bloodstream infections will be assessed. This research is important because identification of risk factors may allow earlier initiation of appropriate therapy in patients infected with these bacteria. Additionally, we will identify whether horizontal spread is responsible for this increasing trend.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Probability Sample

Study Population

linezolid resistance to staph aureus

Criteria

Inclusion Criteria:

patients with linezolid resistance to staphylococcus aureus

Exclusion Criteria:

those that don't meet entry criteria

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00519025

Contacts


Contact: Brian Potoski, PharmD	412-648-6487	potoskiba@upmc.edu

Contact: Diana Lynn Pakstis, RN, BSN	412-648-6553	pakstisdl@dom.pitt.edu

Locations


United States, Pennsylvania
	University of Pittsburgh Medical Center	Recruiting
	Pittsburgh, Pennsylvania, United States, 15213
	Contact: Brian Potoski, PharmD 412-648-6487 potoskiba@upmc.edu
	Contact: Diana Lynn Pakstis, RN, BSN 412-648-6553 pakstisdl@dom.pitt.edu
	Principal Investigator: Brian Potoski, PharmD

Sponsors and Collaborators

University of Pittsburgh

Investigators


Principal Investigator:	Brian Potoski, PharmD	University of Pittsburgh

More Information

Responsible Party:	UPMC ( Brian Potoski, Pharm D )
Study ID Numbers:	PRO07080006, investigator funding
First Received:	August 17, 2007
Last Updated:	February 7, 2008
ClinicalTrials.gov Identifier:	NCT00519025
Health Authority:	United States: Institutional Review Board

Keywords provided by University of Pittsburgh:

Linezolid

Staphylococcus Aureus

Infections

Study placed in the following topic categories:

Linezolid

Additional relevant MeSH terms:

Protein Synthesis Inhibitors

Anti-Infective Agents

Molecular Mechanisms of Pharmacological Action

Therapeutic Uses

Enzyme Inhibitors

Pharmacologic Actions

ClinicalTrials.gov processed this record on August 29, 2008

Sponsored by:	University of Pittsburgh
Information provided by:	University of Pittsburgh
ClinicalTrials.gov Identifier:	NCT00519025